Noven MethyPatch submission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA accepts Noven's June 27 NDA for MethyPatch, a once-daily methylphenidate patch for attention deficit disorder. The NDA, which was previously delayed by "unsuccessful" elements of a Phase III trial, contains two Phase III studies, including a trial in 200 six to 12 year olds showing a statistically significant improvement in attention and behavior versus placebo (Pharmaceutical Approvals Monthly, May 2002, p. 28
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.